Category: Nevin Manimala

J Epidemiol Glob Health. 2024 May 22. doi: 10.1007/s44197-024-00242-4. Online ahead of print.

ABSTRACT

BACKGROUND: This study investigated cause-specific mortality rates in 12 countries during the COVID-19 pandemic in 2020 and 2021.

METHODS: We collected weekly cause-specific mortality data from respiratory disease, pneumonia, cardiovascular disease (CVD) and cancer from national vital statistic databases. We calculated excess mortality for respiratory disease (excluding COVID-19 codes), pneumonia, and CVD in 2020 and 2021 by comparing observed weekly against expected mortality based on historical data (2015-2019), accounting for seasonal trends. We used multilevel regression models to investigate the association between country-level pandemic-related variables and cause-specific mortality.

RESULTS: Significant reductions in cumulative mortality from respiratory disease and pneumonia were observed in 2020 and/or 2021, except for Georgia, Northern Ireland, Kazakhstan, and Ukraine, which exhibited excess mortality for one or both causes. Australia, Austria, Cyprus, Georgia, and Northern Ireland experienced excess cumulative CVD mortality in 2020 and/or 2021. Australia, Austria, Brazil, Cyprus, Georgia, Northern Ireland, Scotland and Slovenia, experienced increased crude cumulative cancer mortality during 2020 and/or 2021 compared to previous years. Among pandemic-related variables, reported COVID-19 incidence was negatively associated with increased cancer mortality, excess respiratory, (2020) and pneumonia (2021) mortality, and positively associated with respiratory and CVD mortality (2021). Stringency of control measures were negatively associated with excess respiratory disease, CVD, and increased cancer mortality (2021).

CONCLUSIONS: This study provides evidence of substantial excess mortality from CVD, and notable reductions in respiratory disease and pneumonia in both years across most countries investigated. Our study also highlights the beneficial impact of stringent control measures in mitigating excess mortality from most causes in 2021.

PMID:38775902 | DOI:10.1007/s44197-024-00242-4

J Med Syst. 2024 May 22;48(1):53. doi: 10.1007/s10916-024-02076-w.

ABSTRACT

Myocardial Infarction (MI) commonly referred to as a heart attack, results from the abrupt obstruction of blood supply to a section of the heart muscle, leading to the deterioration or death of the affected tissue due to a lack of oxygen. MI, poses a significant public health concern worldwide, particularly affecting the citizens of the Chittagong Metropolitan Area. The challenges lie in both prevention and treatment, as the emergence of MI has inflicted considerable suffering among residents. Early warning systems are crucial for managing epidemics promptly, especially given the escalating disease burden in older populations and the complexities of assessing present and future demands. The primary objective of this study is to forecast MI incidence early using a deep learning model, predicting the prevalence of heart attacks in patients. Our approach involves a novel dataset collected from daily heart attack incidence Time Series Patient Data spanning January 1, 2020, to December 31, 2021, in the Chittagong Metropolitan Area. Initially, we applied various advanced models, including Autoregressive Integrated Moving Average (ARIMA), Error-Trend-Seasonal (ETS), Trigonometric seasonality, Box-Cox transformation, ARMA errors, Trend and Seasonal (TBATS), and Long Short Time Memory (LSTM). To enhance prediction accuracy, we propose a novel Myocardial Sequence Classification (MSC)-LSTM method tailored to forecast heart attack occurrences in patients using the newly collected data from the Chittagong Metropolitan Area. Comprehensive results comparisons reveal that the novel MSC-LSTM model outperforms other applied models in terms of performance, achieving a minimum Mean Percentage Error (MPE) score of 1.6477. This research aids in predicting the likely future course of heart attack occurrences, facilitating the development of thorough plans for future preventive measures. The forecasting of MI occurrences contributes to effective resource allocation, capacity planning, policy creation, budgeting, public awareness, research identification, quality improvement, and disaster preparedness.

PMID:38775899 | DOI:10.1007/s10916-024-02076-w

Esophagus. 2024 May 22. doi: 10.1007/s10388-024-01063-x. Online ahead of print.

ABSTRACT

There are various therapeutic options for achalasia. Nevertheless, peroral endoscopic myotomy (POEM) and laparoscopic Heller myotomy with fundoplication (LHM) are distinguished by their efficacy and low incidence of complications. Compare POEM and LHM regarding several outcomes in patients with achalasia. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. An exhaustive literature search was performed using PubMed, Web of Science, and Cochrane Library databases. Studies comparing several outcomes between POEM and LHM in patients with achalasia were included. Data on clinical success, operative time, intraoperative complications, length of stay, reintervention rates, postoperative pain, overall complications, occurrence of GERD symptoms, use of proton bomb inhibitors and esophagitis were extracted. Quality assessment of the included studies was performed using the MINORS scale. We included 20 retrospective observational studies with a combined total of 5139 participants. The results demonstrated that there was no statistically significant difference in terms of intraoperative complications, postoperative complications, reintervention rate, occurrence of GERD symptoms, GERD HRQL, use of proton pump inhibitors, and esophagitis between POEM and LHM groups. Conversely, POEM was associated with higher clinical success and shorter operative time, length of stay, and postoperative pain. This meta-analysis concludes that both POEM and LHM, are effective and safe treatments for achalasia. However, POEM demonstrates better results regarding clinical success, operative time, length of stay, postoperative pain, and a tendency towards lower recurrence.

PMID:38775883 | DOI:10.1007/s10388-024-01063-x

JMIR Public Health Surveill. 2024 May 21;10:e56054. doi: 10.2196/56054.

ABSTRACT

BACKGROUND: The COVID-19 pandemic has exerted a significant toll on individual health and the efficacy of health care systems. However, the influence of COVID-19 on the frequency and outcomes of out-of-hospital cardiac arrest (OHCA) within the Chinese population, both before and throughout the entire pandemic period, remains to be clarified.

OBJECTIVE: This study aimed to fill the gaps by investigating the prevalence and outcomes of OHCA in Hong Kong (HK) both before and during the whole pandemic period.

METHODS: This is a retrospective regional registry study. The researchers matched OHCA data with COVID-19-confirmed case records between December 2017 and May 2023. The data included information on response times, location of OHCA, witness presence, initial rhythm, bystander cardiopulmonary resuscitation (CPR), use of public-access defibrillation, resuscitation in the accident and emergency department, and survival to admission. Descriptive analyses were conducted, and statistical tests such as analysis of variance and χ² were used to examine differences between variables. The incidence of OHCA and survival rates were calculated, and logistic regression analysis was performed to assess associations. The prevalence of OHCA and COVID-19 during the peak of the pandemic was also described.

RESULTS: A total of 43,882 cases of OHCA were reported in HK and included in our analysis. Around 13,946 cases were recorded during the prepandemic period (2017-2019), and the remaining 29,936 cases were reported during the pandemic period (2020-2023). During the pandemic period, the proportion of female patients increased to 44.1% (13,215/29,936), and the average age increased slightly to 76.5 (SD 18.5) years. The majority of OHCAs (n=18,143, 61.1% cases) occurred at home. A witness was present in 45.9% (n=10,723) of the cases, and bystander CPR was initiated in 44.6% (n=13,318) of the cases. There was a significant increase in OHCA incidence, with a corresponding decrease in survival rates compared to the prepandemic period. The location of OHCA shifted, with a decrease in incidents in public places and a potential increase in incidents at home. We found that CPR (odds ratio 1.48, 95% CI 1.17-1.86) and public-access defibrillation (odds ratio 1.16, 95% CI 1.05-1.28) were significantly associated with a high survival to admission rate during the pandemic period. There was a correlation between the development of OHCA and the prevalence of COVID-19 in HK.

CONCLUSIONS: The COVID-19 pandemic has had a significant impact on OHCA in HK, resulting in increased incidence and decreased survival rates. The findings highlight the importance of addressing the indirect effects of the pandemic, such as increased stress levels and strain on health care systems, on OHCA outcomes. Strategies should be developed to improve OHCA prevention, emergency response systems, and health care services during public health emergencies to mitigate the impact on population health.

PMID:38771620 | DOI:10.2196/56054

J Vis. 2024 May 1;24(5):7. doi: 10.1167/jov.24.5.7.

ABSTRACT

This study aimed to investigate the impact of eccentric-vision training on population receptive field (pRF) estimates to provide insights into brain plasticity processes driven by practice. Fifteen participants underwent functional magnetic resonance imaging (fMRI) measurements before and after behavioral training on a visual crowding task, where the relative orientation of the opening (gap position: up/down, left/right) in a Landolt C optotype had to be discriminated in the presence of flanking ring stimuli. Drifting checkerboard bar stimuli were used for pRF size estimation in multiple regions of interest (ROIs): dorsal-V1 (dV1), dorsal-V2 (dV2), ventral-V1 (vV1), and ventral-V2 (vV2), including the visual cortex region corresponding to the trained retinal location. pRF estimates in V1 and V2 were obtained along eccentricities from 0.5° to 9°. Statistical analyses revealed a significant decrease of the crowding anisotropy index (p = 0.009) after training, indicating improvement on crowding task performance following training. Notably, pRF sizes at and near the trained location decreased significantly (p = 0.005). Dorsal and ventral V2 exhibited significant pRF size reductions, especially at eccentricities where the training stimuli were presented (p < 0.001). In contrast, no significant changes in pRF estimates were found in either vV1 (p = 0.181) or dV1 (p = 0.055) voxels. These findings suggest that practice on a crowding task can lead to a reduction of pRF sizes in trained visual cortex, particularly in V2, highlighting the plasticity and adaptability of the adult visual system induced by prolonged training.

PMID:38771584 | DOI:10.1167/jov.24.5.7

JAMA Netw Open. 2024 May 1;7(5):e2411617. doi: 10.1001/jamanetworkopen.2024.11617.

NO ABSTRACT

PMID:38771581 | DOI:10.1001/jamanetworkopen.2024.11617

JAMA Netw Open. 2024 May 1;7(5):e2411656. doi: 10.1001/jamanetworkopen.2024.11656.

NO ABSTRACT

PMID:38771580 | DOI:10.1001/jamanetworkopen.2024.11656

JAMA Netw Open. 2024 May 1;7(5):e2412383. doi: 10.1001/jamanetworkopen.2024.12383.

NO ABSTRACT

PMID:38771579 | DOI:10.1001/jamanetworkopen.2024.12383

JAMA Netw Open. 2024 May 1;7(5):e2412437. doi: 10.1001/jamanetworkopen.2024.12437.

NO ABSTRACT

PMID:38771578 | DOI:10.1001/jamanetworkopen.2024.12437

JAMA Netw Open. 2024 May 1;7(5):e247535. doi: 10.1001/jamanetworkopen.2024.7535.

ABSTRACT

IMPORTANCE: While β-blockers are associated with decreased mortality in cardiovascular disease (CVD), exacerbation-prone patients with chronic obstructive pulmonary disease (COPD) who received metoprolol in the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (BLOCK-COPD) trial experienced increased risk of exacerbations requiring hospitalization. However, the study excluded individuals with established indications for the drug, raising questions about the overall risk and benefit in patients with COPD following acute myocardial infarction (AMI).

OBJECTIVE: To investigate whether β-blocker prescription at hospital discharge is associated with increased risk of mortality or adverse cardiopulmonary outcomes in patients with COPD and AMI.

DESIGN, SETTING, AND PARTICIPANTS: This prospective, longitudinal cohort study with 6 months of follow-up enrolled patients aged 35 years or older with COPD who underwent cardiac catheterization for AMI at 18 BLOCK-COPD network hospitals in the US from June 2020 through May 2022.

EXPOSURE: Prescription for any β-blocker at hospital discharge.

MAIN OUTCOMES AND MEASURES: The primary outcome was time to the composite outcome of death or all-cause hospitalization or revascularization. Secondary outcomes included death, hospitalization, or revascularization for CVD events, death or hospitalization for COPD or respiratory events, and treatment for COPD exacerbations.

RESULTS: Among 3531 patients who underwent cardiac catheterization for AMI, prevalence of COPD was 17.1% (95% CI, 15.8%-18.4%). Of 579 total patients with COPD and AMI, 502 (86.7%) were prescribed a β-blocker at discharge. Among the 562 patients with COPD included in the final analysis, median age was 70.0 years (range, 38.0-94.0 years) and 329 (58.5%) were male; 553 of the 579 patients (95.5%) had follow-up information. Among those discharged with β-blockers, there was no increased risk of the primary end point of all-cause mortality, revascularization, or hospitalization (hazard ratio [HR], 1.01; 95% CI, 0.66-1.54; P = .96) or of cardiovascular events (HR, 1.11; 95% CI, 0.65-1.92; P = .69), COPD-related or respiratory events (HR, 0.75; 95% CI, 0.34-1.66; P = .48), or treatment for COPD exacerbations (rate ratio, 1.01; 95% CI, 0.53-1.91; P = .98).

CONCLUSIONS AND RELEVANCE: In this cohort study, β-blocker prescription at hospital discharge was not associated with increased risk of adverse outcomes in patients with COPD and AMI. These findings support use of β-blockers in patients with COPD and recent AMI.

PMID:38771577 | DOI:10.1001/jamanetworkopen.2024.7535